Document is current
Any future updates will be listed below
-
Authors
Cleeland, Charles S. https://orcid.org/0000-0002-1460-6527
Keating, Karen N. https://orcid.org/0000-0001-6993-3114
Cuffel, Brian https://orcid.org/0000-0003-0205-0530
Elbi, Cem https://orcid.org/0000-0002-1327-3476
Siegel, Jonathan M. https://orcid.org/0000-0001-6477-4281
Gerlinger, Christoph https://orcid.org/0000-0003-4538-6413
Symonds, Tara
Sloan, Jeff A. https://orcid.org/0000-0002-3393-2387
Dueck, Amylou C. https://orcid.org/0000-0002-9912-1085
Bottomley, Andrew https://orcid.org/0000-0002-3067-5207
Wang, Xin Shelley https://orcid.org/0000-0003-2348-8005
Williams, Loretta A. https://orcid.org/0000-0003-2788-657X
Mendoza, Tito R. https://orcid.org/0000-0001-8122-5233
-
Funding
Funding for this research was provided by:
Bayer HealthCare Pharmaceuticals
National Institutes of Health
- License Information
-
More Information
Article History
Received: 16 April 2023
Accepted: 15 May 2024
First Online: 27 June 2024
Competing interests
: The MD Anderson Symptom Inventory (MDASI) and its derivative versions are copyrighted and licensed by The University of Texas MD Anderson Cancer Center and Charles S. Cleeland. Charles S. Cleeland and Xin Shelley Wang have a financial interest in the MDASI and its derivative versions. Karen N. Keating, Brian Cuffel, Cem Elbi, Jonathan M. Siegel, and Christoph Gerlinger are employees of Bayer and hold stock in Bayer. Charles Cleeland, Xin Shelley Wang, Tito Mendoza, and Loretta Williams have received research funding from Bayer. The authors declare that they have no other competing interests.
